Barnwell Industries is engaged in the business of: acquiring, developing, producing and selling oil and natural gas in Canada including evaluating proposals by third parties with regard to participation in exploratory and developmental operations elsewhere; investing in land interests in Hawaii; and drilling water and water monitoring wells of varying depths in Hawaii, installing and repairing water pumping systems through its wholly-owned subsidiary, Water Resources International, Inc., which is the distributor for Floway pumps and equipment in the state of Hawaii.

Dorchester Minerals is engaged in the acquisition, ownership and administration of Royalty Properties and Net Profits Interests (NPIs). The Royalty Properties consist of producing and nonproducing mineral, royalty, overriding royalty, net profits, and leasehold interests located in several counties and parishes in several states. The NPIs represent net profits overriding royalty interests in various properties owned by the operating partnership. The company's general partner is Dorchester Minerals Management LP, which is managed by its general partner, Dorchester Minerals Management GP LLC.

JMP Group is a holding company. Through its subsidiaries, the company is a capital markets firm. The company provides investment banking, sales and trading, and equity research services to corporate and institutional clients as well as alternative asset management products and services to institutional investors and individuals. In addition, the company manages and invests in corporate credit instruments through collateralized loan obligations and direct investments, and it serves as the investment advisor to a business development company. The company's investment banking provides capital raising services, mergers and acquisitions transaction services, and other advisory services to corporate clients.

Molecular Templates is a clinical-stage company focused on the discovery and development of biologic therapeutic for cancer and other serious diseases. The company utilizes its proprietary biologic drug platform to design and generate engineered toxin bodies (ETBs). The company is developing ETBs for various targets, including CD20, CD38, HER2, PD-L1, CTLA-4, SLAMF-7, and CD45. CD20 is central to B cell malignancies and is clinically validated as a target for the treatment of lymphomas and autoimmune disease. CD38 has been validated as a clinical target in the treatment of various myeloma. PD-L1 is central to immune checkpoint pathways and is a target expressed in a variety of solid tumor cancers.

Sumo Group is engaged in the development of video games providing both turnkey and co-development solutions. Co.'s development solution, includes initial concept and pre-production, production and development, and post-release support. Co. develops games across all console platforms, PC, handheld and mobile devices.